Coherus Oncology (CHRS) Non-Current Deferred Tax Liability (2023 - 2026)
Coherus Oncology (CHRS) posted Non-Current Deferred Tax Liability of $1.1 million for Q1 2026, little changed sequentially from $1.1 million in Q4 2025, and little changed YoY from $1.1 million in Q1 2025.
Coherus Oncology (CHRS) Non-Current Deferred Tax Liability (2023 - 2026) Analysis & Trends
Coherus Oncology has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed 0.0% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (changed 0.0% YoY) and the FY2025 annual result came in at $1.1 million, changed 0.0% from the prior year.
- Non-Current Deferred Tax Liability was little changed at $1.1 million in Q1 2026 per CHRS's latest filing, from $1.1 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $1.1 million in Q3 2023 and troughed at $1.1 million in Q3 2023.
- A 4-year average of $1.1 million and a median of $1.1 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- The widest YoY moves for Non-Current Deferred Tax Liability: up 0.0% in 2024, down 0.0% in 2024.
- Over 4 years, Non-Current Deferred Tax Liability stood at $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $1.1 million, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Mn |
| Jun 30, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |